All In Biotech

Drug Trial Radar · NCT03320330

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Jan 31, 2018

Primary completion

Dec 31, 2020

Study completion Jun 30, 2024

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of pepinemab and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Recurrent Malignant Solid Neoplasm
  • Recurrent Osteosarcoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Osteosarcoma

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PepinemabBiological

    Given IV

  • Pharmacological StudyOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting ToxicitiesTime frame: Up to 28 days
  2. Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE'Time frame: Up to 28 days
  3. Half-lifeTime frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
  4. Time to Maximum Concentration (T Max)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
  5. Maximum Concentration (C Max)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
  6. Area Under Curve (AUC)Time frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
  7. ClearanceTime frame: Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+
  8. Disease Control Rate (Part A)Time frame: Up to 4 months
  9. Response (Complete Response or Partial Response) (Part B)Time frame: Up to 168 days

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta - Egleston

    Atlanta, Georgia

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • C S Mott Children's Hospital

    Ann Arbor, Michigan

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Saint Jude Children's Research Hospital

    Memphis, Tennessee

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

    Houston, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.